Search by Drug Name or NDC
NDC 00078-0916-61 KISQALI FEMARA CO-PACK Details
KISQALI FEMARA CO-PACK
KISQALI FEMARA CO-PACK is a KIT in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is .
MedlinePlus Drug Summary
Letrozole is used treat early breast cancer in women who have experienced menopause (change of life; end of monthly menstrual periods) and who have had other treatments, such as radiation or surgery to remove the tumor. It is also used to treat early breast cancer in women who have experienced menopause and who have already been treated with a medication called tamoxifen (Nolvadex) for 5 years. Letrozole is also used in women who have experienced menopause as a first treatment of breast cancer that has spread within the breast or to other areas of the body or in women whose breast cancer has worsened while they were taking tamoxifen. Letrozole is in a class of medications called nonsteroidal aromatase inhibitors. It works by decreasing the amount of estrogen produced by the body. This can slow or stop the growth of some types of breast cancer cells that need estrogen to grow.
Related Packages: 00078-0916-61Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Letrozole
Ribociclib is used in combination with another medication to treat a certain type of hormone receptor–positive (depends on hormones such as estrogen to grow) advanced breast cancer or that has spread to other parts of the body in women who have not experienced menopause (change of life; end of monthly menstrual periods) and in those who are close to or who have already experienced menopause. Ribociclib is also used in combination with fulvestrant (Faslodex) to treat a certain type of hormone receptor–positive advanced breast cancer or that has spread to other parts of the body as an initial treatment or in people who have not been treated successfully with other treatments in women who have already experienced menopause. Ribociclib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.
Related Packages: 00078-0916-61Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Ribociclib
Product Information
NDC | 00078-0916 |
---|---|
Product ID | 0078-0916_5740112b-a7e5-47ec-955b-f25ad9c4344e |
Associated GPIs | 2199000260B740 |
GCN Sequence Number | 077381 |
GCN Sequence Number Description | ribociclib succinate/letrozole TABLET 400-2.5 MG ORAL |
HIC3 | V31 |
HIC3 Description | ANTINEOPLASTIC COMB - KINASE AND AROMATASE INHIBIT |
GCN | 43368 |
HICL Sequence Number | 044246 |
HICL Sequence Number Description | RIBOCICLIB SUCCINATE/LETROZOLE |
Brand/Generic | Brand |
Proprietary Name | KISQALI FEMARA CO-PACK |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | letrozole and ribociclib |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | KIT |
Route | n/a |
Active Ingredient Strength | n/a |
Active Ingredient Units | n/a |
Substance Name | n/a |
Labeler Name | Novartis Pharmaceuticals Corporation |
Pharmaceutical Class | n/a |
DEA Schedule | n/a |
Marketing Category | NDA |
Application Number | NDA209935 |
Listing Certified Through | 2024-12-31 |
Package
NDC 00078-0916-61 (00078091661)
NDC Package Code | 0078-0916-61 |
---|---|
Billing NDC | 00078091661 |
Package | 1 KIT in 1 KIT (0078-0916-61) * 28 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0078-0881-50) * 14 TABLET in 1 BLISTER PACK (0078-0895-14) |
Marketing Start Date | 2017-05-04 |
NDC Exclude Flag | N |
Pricing Information | N/A |